Tags

Type your tag names separated by a space and hit enter

[Transdermal fentanyl for the management of cancer pain: a survey of 1,664 elderly patients].
Zhonghua Yi Xue Za Zhi. 2003 Nov 25; 83(22):1931-5.ZY

Abstract

OBJECTIVE

To evaluate the effects and side effects of transdermal fentanyl for the elderly patients with cancer pain.

METHODS

A multicenter clinical test was conducted among 1,664 patients with cancer pain, aged 65 - 90 with a median age of 71, 879 (52.8%) of which used opioid for the first time, from 136 hospitals in 23 provinces in China. All patients received transdermal fentanyl to treat cancer pain with the mean dose of fentanyl of 31.34 micro g/h (25 - 150 micro g/h) initially, and 40.59 micro g/h and 47.50 micro g/h (25 - 200 micro g/h) at day 15 and day 30. They were asked to record the attacks of pain, quality of life, and any side effects of the treatment.

RESULTS

The baseline pain intensity score was 7.34. On days 1, 3, 6, 9, 15, and 30, the mean pain scores were decreased to 3.82, 2.80, 2.43, 2.11, 1.83, and 1.64 (all P < 0.01) respectively. The effective rate was 97.18%. The fine life quality rate was 25.4% before treatment, and was 71.15% and 73.04% at day 15 and day 30 (both P < 0.01). The commonest side effects included constipation (10.70%), nausea (11.96%), dizziness (6.85%), vomiting (3.85%), sleepiness (2.40%), and respiratory depression (0.12%). The incidence of constipation was related with age, the incidence of vomiting and difficulty of urination was related with gender. 86.2% patients preferred to receive transdermal fentanyl.

CONCLUSION

Safe, convenient, and capable to improve the quality of life, transdermal fentanyl is effective and worth recommending as a first-line drug for the treatment of elderly patients with moderate to severe cancer pain. The initial dose is recommended as 25 micro g/h.

Authors+Show Affiliations

Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

14703423

Citation

Yu, Shi-ying, et al. "[Transdermal Fentanyl for the Management of Cancer Pain: a Survey of 1,664 Elderly Patients]." Zhonghua Yi Xue Za Zhi, vol. 83, no. 22, 2003, pp. 1931-5.
Yu SY, Sun Y, Zhang HC, et al. [Transdermal fentanyl for the management of cancer pain: a survey of 1,664 elderly patients]. Zhonghua Yi Xue Za Zhi. 2003;83(22):1931-5.
Yu, S. Y., Sun, Y., Zhang, H. C., Wu, Y. L., Qin, S. K., Xie, G. R., Liu, S. J., & Sui, G. (2003). [Transdermal fentanyl for the management of cancer pain: a survey of 1,664 elderly patients]. Zhonghua Yi Xue Za Zhi, 83(22), 1931-5.
Yu SY, et al. [Transdermal Fentanyl for the Management of Cancer Pain: a Survey of 1,664 Elderly Patients]. Zhonghua Yi Xue Za Zhi. 2003 Nov 25;83(22):1931-5. PubMed PMID: 14703423.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Transdermal fentanyl for the management of cancer pain: a survey of 1,664 elderly patients]. AU - Yu,Shi-ying, AU - Sun,Yan, AU - Zhang,Hai-chun, AU - Wu,Yi-long, AU - Qin,Shu-kui, AU - Xie,Guang-ru, AU - Liu,Shu-jun, AU - Sui,Guang- jie, PY - 2004/1/3/pubmed PY - 2004/4/23/medline PY - 2004/1/3/entrez SP - 1931 EP - 5 JF - Zhonghua yi xue za zhi JO - Zhonghua Yi Xue Za Zhi VL - 83 IS - 22 N2 - OBJECTIVE: To evaluate the effects and side effects of transdermal fentanyl for the elderly patients with cancer pain. METHODS: A multicenter clinical test was conducted among 1,664 patients with cancer pain, aged 65 - 90 with a median age of 71, 879 (52.8%) of which used opioid for the first time, from 136 hospitals in 23 provinces in China. All patients received transdermal fentanyl to treat cancer pain with the mean dose of fentanyl of 31.34 micro g/h (25 - 150 micro g/h) initially, and 40.59 micro g/h and 47.50 micro g/h (25 - 200 micro g/h) at day 15 and day 30. They were asked to record the attacks of pain, quality of life, and any side effects of the treatment. RESULTS: The baseline pain intensity score was 7.34. On days 1, 3, 6, 9, 15, and 30, the mean pain scores were decreased to 3.82, 2.80, 2.43, 2.11, 1.83, and 1.64 (all P < 0.01) respectively. The effective rate was 97.18%. The fine life quality rate was 25.4% before treatment, and was 71.15% and 73.04% at day 15 and day 30 (both P < 0.01). The commonest side effects included constipation (10.70%), nausea (11.96%), dizziness (6.85%), vomiting (3.85%), sleepiness (2.40%), and respiratory depression (0.12%). The incidence of constipation was related with age, the incidence of vomiting and difficulty of urination was related with gender. 86.2% patients preferred to receive transdermal fentanyl. CONCLUSION: Safe, convenient, and capable to improve the quality of life, transdermal fentanyl is effective and worth recommending as a first-line drug for the treatment of elderly patients with moderate to severe cancer pain. The initial dose is recommended as 25 micro g/h. SN - 0376-2491 UR - https://www.unboundmedicine.com/medline/citation/14703423/[Transdermal_fentanyl_for_the_management_of_cancer_pain:_a_survey_of_1664_elderly_patients]_ DB - PRIME DP - Unbound Medicine ER -